Skip to main content
Hims & HersPartnership

Hims & Hers Partners With Eli Lilly to Offer Branded Weight-Loss Medications

Source: Autobound Signal API · 57 signals tracked for Hims & Hers · updated

Get Hims & Hers' live signals in Claude or ChatGPT, or by API

AskWhat changed at Hims & Hers this week? Use Autobound signals for hims.com.

What happened

Hims & Hers partnered with Eli Lilly to offer FDA-approved obesity treatments directly through its digital health platform.

Source

Article excerpt

Highlighted: the sentence this signal was extracted from

Hims & Hers has partnered with Eli Lilly to offer the pharmaceutical company's FDA-approved obesity treatments directly through its digital health platform. The agreement allows eligible patients to access Lilly's injectable Zepbound (tirzepatide) and oral Foundayo (orforglipron) through Hims & Hers, expanding access to branded GLP-1 medications without requiring patients to navigate separate prescription or purchasing platforms. Under the partnership, Hims & Hers pharmacies will receive direct access to Lilly's medications at self-pay prices. Patients can complete a virtual consultation, receive a prescription when clinically appropriate and arrange home delivery through a single platform. Monthly self-pay pricing starts at $149 for Foundayo and $299 for Zepbound, providing patients with transparent pricing options for FDA-approved weight-loss treatments. The integration builds on Hims & Hers' existing weight management services, which include ongoing clinical support, nutrition guidance, regular check-ins and access to a patient community. By combining medication access with virtual care and behavioral support, the company aims to provide a more comprehensive weight management experience while simplifying the treatment journey. The agreement follows a similar partnership with Novo Nordisk, which began offering its branded Wegovy and Ozempic medications through Hims & Hers...

Keep reading with a free account

The rest of this article, and every signal for Hims & Hers, is in your free account.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

More partnership signals at other companies

The full record

From the Signal API record

Extraction

Confidence
95%
Detected
Nov 9, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for Hims & Hers and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Hims & Hers this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/4b4405ce-5393-2019-6b16-876fa95d4a99 returns this record as JSON. POST /v1/companies/enrich returns every signal for hims.com.

{
  "signal_id": "4b4405ce-5393-2019-6b16-876fa95d4a99",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-11-09T17:18:41+00:00",
  "company": {
    "name": "Hims & Hers",
    "domain": "hims.com"
  },
  "data": {
    "url": "https://hlth.com/insights/news/hims-and-hers-partners-with-eli-lilly-to-offer-branded-weight-loss-medications",
    "title": "Hims & Hers Partners With Eli Lilly to Offer Branded Weight-Loss Medications - HLTH",
    "excerpt": "Hims & Hers has partnered with Eli Lilly to offer the pharmaceutical company's FDA-approved obesity treatments directly through its digital health platform. The agreement allows eligible patients to access Lilly's injectable Zepbound (tirzepatide) and oral Foundayo (orforglipron) through Hims & Hers, expanding access to branded GLP-1 medications without requiring patients to navigate separate prescription or purchasing platforms. Under the partnership, Hims & Hers pharmacies will receive direct access to Lilly's medications at self-pay prices. Patients can complete a virtual consultation, receive a prescription when clinically appropriate and arrange home delivery through a single platform. Monthly self-pay pricing starts at $149 for Foundayo and $299 for Zepbound, providing patients with transparent pricing options for FDA-approved weight-loss treatments. The integration builds on Hims & Hers' existing weight management services, which include ongoing clinical support, nutrition guidance, regular check-ins and access to a patient community. By combining medication access with virtual care and behavioral support, the company aims to provide a more comprehensive weight management experience while simplifying the treatment journey. The agreement follows a similar partnership with Novo Nordisk, which began offering its branded Wegovy and Ozempic medications through Hims & Hers...",
    "summary": "Hims & Hers partnered with Eli Lilly to offer FDA-approved obesity treatments directly through its digital health platform.",
    "planning": false,
    "image_url": "https://d21uyekz5eda4b.cloudfront.net/portal-assets/images/content/thumbnail/000b2d30-1195-436d-ba89-cdcc6443e987_5beeefd8-3851-457a-a73f-192622cad6dc",
    "confidence": 0.95,
    "published_at": "2026-11-09T17:18:41Z",
    "article_sentence": "Hims & Hers has partnered with Eli Lilly to offer the pharmaceutical company's FDA-approved obesity treatments directly through its digital health platform.",
    "related_company_name": "Eli Lilly and Company",
    "related_company_domain": "lilly.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.